Adherence to recommendations for secondary prevention medications after myocardial infarction in Estonia: comparison of real-world data from 2004 to 2005 and 2017 to 2018

[1] Mensah GA(2017)Decline in cardiovascular mortality: possible causes and implications Circa Res 120 366-380

[2] Wei GS(2013)2013 ESC guidelines on the management of stable coronary artery disease—addenda Eur Heart J 34 2949-3003

[3] Sortie PD(2002)Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world Heart 88 119-124

[4] Fine LJ(2017)High adherence to therapy and low cardiac mortality and morbidity in patients after acute coronary syndrome systematically managed by office-based cardiologists in Germany: 1-year outcomes of the Pronator Study Vasc Health Risk Manag 2017 127-137

[5] Rosenberg Y(2019)Post-myocardial infarction (MI) care: medication adherence for secondary prevention after MI in a large real-world population Clin Ther 41 107-117

[6] Kaufmann PG(2019)Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry Eur J Prev Cardiol 26 824-835

[7] Sachem U(2016)Assessing the impact of medication adherence on long-term cardiovascular outcomes J Am Coll Cardiol 68 789-801

[8] Achenbach S(2010)Use of evidence-based pharmacotherapy after myocardial infarction in Estonia BMC Public Health 10 358-2381

[9] Andreotti F(2016)2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur Heart J 37 2315-32

[10] Arden C(2018)The risk-treatment paradox in non-ST-elevation myocardial infarction patients according to their estimated GRACE risk Int J Cardiol 272 26-230

[1] Mensah GA(2017)Decline in cardiovascular mortality: possible causes and implications Circa Res 120 366-380

[2] Wei GS(2013)2013 ESC guidelines on the management of stable coronary artery disease—addenda Eur Heart J 34 2949-3003

[3] Sortie PD(2002)Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world Heart 88 119-124

[4] Fine LJ(2017)High adherence to therapy and low cardiac mortality and morbidity in patients after acute coronary syndrome systematically managed by office-based cardiologists in Germany: 1-year outcomes of the Pronator Study Vasc Health Risk Manag 2017 127-137

[5] Rosenberg Y(2019)Post-myocardial infarction (MI) care: medication adherence for secondary prevention after MI in a large real-world population Clin Ther 41 107-117

[6] Kaufmann PG(2019)Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry Eur J Prev Cardiol 26 824-835

[7] Sachem U(2016)Assessing the impact of medication adherence on long-term cardiovascular outcomes J Am Coll Cardiol 68 789-801

[8] Achenbach S(2010)Use of evidence-based pharmacotherapy after myocardial infarction in Estonia BMC Public Health 10 358-2381

[9] Andreotti F(2016)2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur Heart J 37 2315-32

[10] Arden C(2018)The risk-treatment paradox in non-ST-elevation myocardial infarction patients according to their estimated GRACE risk Int J Cardiol 272 26-230